Previous 10 | Next 10 |
Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 met the main goal of a global phase 2/3 trial. The Chinese company added that in the trial — which enrolled 1,278 people — SCB-2019 (CpG 1018/Alum) elicited almost 2-fold higher neutralizing a...
-- SCB-2019 (CpG 1018/Alum) elicited approximately 2-fold higher neutralizing antibody titers in adolescents (aged 12 to 17 years) compared to young adults (aged 18 to 25 years) -- -- Favorable tolerability and safety profile in adolescents, consistent with results previously ob...
Earlier this month, Dynavax and Novavax both reported Q2 2022 earnings as the pandemic has eased around the world. Dramatic differences between the Alphavaxers' revised 2022 guidances point to real differences between the two. Non-COVID assets will likely become increasingly impor...
The World Health Organization (WHO) on Thursday recommended VLA2001, the inactivated whole-virus COVID-19 vaccine, developed by French vaccine maker Valneva ( NASDAQ: VALN ) for the prevention of coronavirus disease. The decision follows the WHO’s Strategic Advisory...
Image source: The Motley Fool. Dynavax Technologies (NASDAQ: DVAX) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Dynavax Technologies (DVAX) Q2 2022 Earnings Call Transcript
One of the more up-and-down coronavirus stocks, Dynavax Technologies (NASDAQ: DVAX) , had quite the up day on Friday. The company's shares had levitated by almost 18% late in the session after it delivered its latest set of quarterly figures. For its second quarter, the results ...
We are revisiting Dynavax Technologies after this vaccine concern just posted robust quarterly results that easily exceeded expectations. The company continues to gain market share with its Hepatitis B vaccine and is seeing huge revenue growth from its Covid-19 efforts. What's nex...
Dynavax Technologies Corporation (DVAX) Q2 2022 Earnings Conference Call August 4, 2022 04:30 PM ET Company Participants Nicole Arndt – Senior Manager for Investor Relations Ryan Spencer – Chief Executive Officer Donn Casale – Senior Vice Pre...
The following slide deck was published by Dynavax Technologies Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Dynavax Technologies Corporation 2022 Q2 - Results - Earnings Call Presentation
Dynavax Technologies ( NASDAQ: DVAX ) is up 8% in after-hours trading after upping its 2022 guidance for revenue of its key product, the vaccine adjuvant CpG 1018. The company now expects 2022 sales of CpG 1018 of $550M-$600M. In May, it was projected at $550M. CpG...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...